August 2012
-
Inhaler testing instrument company Copley Scientific has announced the appointment of Anna Sipitanou as Business Development Manager. Sipitanou was most recently Business Development Manager at Cellomatics Biosciences, and her prior experience includes development of IVIVC… Read more . . .
-
Theravance Biopharma and Mylan have announced that a 12-month Phase 3 safety study of nebulized revefenacin (TD-4208) showed that the drug was well tolerated, with low rates of adverse events and serious adverse events that… Read more . . .
-
Opiant Pharmaceuticals has announced results from a Phase 1 trial of OPNT002 intranasal naltrexone, which it is developing for the treatment of alcohol use disorder (AUD). According to the company, which recently announced that it… Read more . . .
-
Dewmar International says that it has filed a provisional patent application titled “Cannabinoid Formulation to Treat Lung Cancer” with the United States Patent and Trademark Office (USPTO). The companies current brands include “Kush Cakes” psychedelic… Read more . . .
-
Samumed has announced positive results from a Phase I trial of an inhalation solution of its novel Wnt signaling modulator SM04646, which the company is developing for the treatment of idiopathic pulmonary fibrosis (IPF). The… Read more . . .
-
Perrigo announced that it has settled Hatch-Waxman litigation brought by Meda Pharmaceuticals and Cipla regarding Dymista azelastine HCl/fluticasone propionate nasal spray. Meda’s NDA for Dymista was approved by the FDA for the treatment of allergic… Read more . . .
-
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has announced the reclassification of Nasonex mometasone furoate nasal spray from a “POM,” or “prescription only medicine,” to a “P” medicine, available over the counter at… Read more . . .
-
Sunovion has announced that it has agreed to divest US rights to the Alvesco ciclesonide MDI for the treatment of asthma and the Omnaris and Zetonna ciclesonide nasal sprays for the treatment of allergic rhinitis… Read more . . .
-
MannKind Corporation has announced the appointment of Patrick McCauley as Chief Commercial Officer, effective immediately. McCauley was most recently Area VP, West US, Urulogy/PCP Sales for Astellas Pharma and had served in various sales and… Read more . . .
-
During a July 11, 2017 meeting between AstraZeneca CEO Pascal Soriot and Australian Prime Minister Malcolm Turnbull, Soriot announced an A$100 million expansion of the company’s manufacturing facility in Sydney, which he called “really a… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland